Table 1.
Summary of Patient Characteristics at HAART Initiation
| FH-Argentina (n=794) |
HUCFF-Brazil (n=522) |
FA-Chile (n=547) |
GHESKIO-Haiti (n=1672) |
IHSS/HE- Honduras y(n=328) |
INNSZ-Mexico (n=416) |
IMTAvH-Peru (n=873) |
Combined (n=5152) |
|
|---|---|---|---|---|---|---|---|---|
| Female | 233 (29.3%) | 175 (33.5%) | 70 (12.8%) | 893 (53.4%) | 129 (39.3%) | 52 (12.5%) | 260 (29.8%) | 1812 (35.2%) |
| Age | 35 (30, 43)a | 37 (32, 45) | 36 (30, 42) | 39 (33, 45) | 37 (31, 41) | 35 (29, 42) | 34 (28, 41) | 37 (31, 43) |
| Route of Infection | ||||||||
| Missing | 214 (27%) | 170 (32.6%) | 6 (1.1%) | 1672 (100%) | 0 (0%) | 0 (0%) | 6 (0.7%) | 2068 (40.1%) |
| Heterosexual | 278 (47.9%)b | 219 (62.2%) | 161 (29.8%) | - | 327 (99.7%)c | 149 (35.8%) | 594 (68.5%) | 1728 (56%)c |
| IVDU | 77 (13.3%) | 7 (2%) | 2 (0.4%) | - | 1 (0.3%) | 0 (0%) | 0 (0%) | 87 (2.8%) |
| MSM | 222 (38.3%) | 106 (30.1%) | 378 (69.9%) | - | 0 (0%) | 264 (63.5%) | 272 (31.4%) | 1242 (40.3%) |
| Other | 3 (0.5%) | 20 (5.7%) | 0 (0%) | - | 0 (0%) | 3 (0.7%) | 1 (0.1%) | 27 (0.9%) |
| Clinical Stage | ||||||||
| Missing | 4 (0.4%) | 160 (25.4%) | 2 (0.3%) | 0 (0%) | 10 (2.2%) | 12 (2.1%) | 39 (2.9%) | 227 (4.6%) |
| not AIDS | 541 (68.5%) | 95 (26.2%) | 302 (55.4%) | 954 (57.1%) | 189 (59.4%) | 226 (55.9%) | 312 (37.4%) | 2619 (53.2%) |
| AIDS | 249 (31.5%) | 267 (73.8%)d | 243 (44.6%) | 718 (42.9%) | 129 (40.6%) | 178 (44.1%) | 522 (62.6%) | 2306 (46.8%)d |
| CD4 (cells/μL) | 163 (55, 250) | 153 (53, 240) | 116 (32, 193) | 102 (37, 191) | 105 (55, 185) | 88 (33, 192) | 79 (32, 166) | 107 (39, 201) |
| Missing | 107 (13.5%) | 190 (36.4%) | 108 (19.7%) | 224 (13.4%) | 68 (20.7%) | 18 (4.3%) | 170 (19.5%) | 885 (17.2%) |
| < 50 | 160 (23.3%) | 80 (24.1%) | 142 (32.3%) | 445 (30.7%) | 49 (18.8%) | 137 (34.4%) | 260 (37%) | 1273 (29.8%) |
| 50–99 | 91 (13.2%) | 51 (15.4%) | 65 (14.8%) | 262 (18.1%) | 76 (29.2%) | 74 (18.6%) | 147 (20.9%) | 766 (18%) |
| 100–199 | 178 (25.9%) | 78 (23.5%) | 133 (30.3%) | 410 (28.3%) | 79 (30.4%) | 96 (24.1%) | 168 (23.9%) | 1142 (26.8%) |
| 200–349 | 179 (26.1%) | 102 (30.7%) | 91 (20.7%) | 284 (19.6%) | 48 (18.5%) | 84 (21.1%) | 100 (14.2%) | 888 (20.8%) |
| ≥ 350 | 79 (11.5%) | 21 (6.3%) | 8 (1.8%) | 47 (3.2%) | 8 (3.1%) | 7 (1.8%) | 28 (4%) | 198 (4.6%) |
| CD4<200 or AIDS | ||||||||
| Missing | 2 (0.3%) | 59 (11.3%) | 2 (0.4%) | 0 (0%) | 8 (2.4%) | 1 (0.2%) | 12 (1.4%) | 84 (1.6%) |
| not Advanced | 293 (37%) | 116 (25.1%) | 96 (17.6%) | 347 (21.7%) | 72 (22.5%) | 74 (17.8%) | 132 (15.3%) | 1130 (22.2%) |
| Advanced | 499 (63%) | 347 (74.9%) | 449 (82.4%) | 1310 (78.3%) | 248 (77.5%) | 341 (82.2%) | 729 (84.7%) | 3938 (76.1%) |
| HIV-1 RNA (log10) | 5 (4.4, 5.4) | 4.7 (3.6, 5.2) | 5.1 (4.7, 5.5) | - | 5 (4.7, 5) | 4.9 (4.9, 4.9) | 5.2 (4.7, 5.5) | 5 (4.6, 5.4) |
| Missing | 236 (29.7%) | 371 (71.1%) | 162 (29.6%) | 1672 (100%) | 234 (71.3%) | 58 (13.9%) | 383 (43.9%) | 3116 (60.5%) |
| < 10,000 | 208 (37.3%) | 45 (29.8%) | 139 (36.1%) | - | 25 (26.6%) | 267 (74.6%) | 132 (26.9%) | 816 (40.1%) |
| 10,000–99,999 | 76 (13.6%) | 49 (32.5%) | 22 (5.7%) | - | 12 (12.8%) | 15 (4.2%) | 59 (12%) | 233 (11.4%) |
| ≥ 100,000 | 274 (49.1%) | 57 (37.7%) | 224 (58.2%) | - | 57 (60.6%) | 76 (21.2%) | 299 (61%) | 987 (48.5%) |
| Weight (kg) | 65 (58, 74) | 65 (58, 74) | 64 (56, 72) | 53 (46, 60) | 59 (51, 65) | 61 (53, 71) | 57 (50, 64) | 56 (49, 64) |
| Missing | 715 (90.1%) | 399 (76.4%) | 326 (59.6%) | 99 (5.9%) | 95 (29%) | 106 (25.5%) | 217 (24.9%) | 1957 (38%) |
| Hemoglobin (g/dL) | 13.7 (11.9, 14.6) | 11.7 (10, 13.7) | 12.3 (10.7, 13.7) | 10 (9, 11) | 12.3 (10.8, 13.5) | 14.1 (11.8, 15.7) | 11.3 (10.1, 12.7) | 11 (9.8, 12.9) |
| Missing | 770 (97%) | 267 (51.1%) | 343 (62.7%) | 541 (32.4%) | 147 (44.8%) | 165 (39.7%) | 696 (79.7%) | 2929 (56.9%) |
| Calendar Year | ||||||||
| 1996–1999 | 6 (0.8%) | 136 (26.1%) | 0 (0%) | 0 (0%) | 3 (0.9%) | 0 (0%) | 5 (0.6%) | 150 (2.9%) |
| 2000–2001 | 43 (5.4%) | 124 (23.8%) | 35 (6.4%) | 0 (0%) | 5 (1.5%) | 3 (0.7%) | 11 (1.3%) | 221 (4.3%) |
| 2002–2003 | 232 (29.2%) | 118 (22.6%) | 290 (53%) | 709 (42.4%) | 104 (31.7%) | 147 (35.3%) | 50 (5.7%) | 1650 (32%) |
| 2004–2005 | 355 (44.7%) | 80 (15.3%) | 222 (40.6%) | 939 (56.2%) | 100 (30.5%) | 161 (38.7%) | 525 (60.1%) | 2382 (46.2%) |
| 2006–2007 | 158 (19.9%) | 64 (12.3%) | 0 (0%) | 24 (1.4%) | 116 (35.4%) | 105 (25.2%) | 282 (32.3%) | 749 (14.5%) |
| Initial Regimen | ||||||||
| NNRTI | 513 (64.6%) | 288 (55.2%) | 510 (93.2%) | 1594 (95.3%) | 315 (96%) | 289 (69.5%) | 806 (92.3%) | 4315 (83.8%) |
| PI | 28 (3.5%) | 167 (32%) | 24 (4.4%) | 15 (0.9%) | 10 (3%) | 16 (3.8%) | 21 (2.4%) | 281 (5.5%) |
| Boosted PI | 205 (25.8%) | 43 (8.2%) | 4 (0.7%) | 7 (0.4%) | 2 (0.6%) | 106 (25.5%) | 37 (4.2%) | 404 (7.8%) |
| Other | 48 (6%) | 24 (4.6%) | 9 (1.6%) | 56 (3.3%) | 1 (0.3%) | 5 (1.2%) | 9 (1%) | 152 (3%) |
a
Continuous variables are reported as medians (interquartile range).
b
Percentages are computed using the number of patients with a non-missing value.
c
IHSS/HE-Honduras did not differentiate between heterosexual and MSM routes of infection. All are listed here as heterosexual.
d
HUCFF-Brazil classified most patients with CD4<200 as having clinical AIDS.